F585 CASE STUDY 2015

A summary of different nanoparticles used for drug delivery applications in cancer are presented. Like gold, carbon nanotubes can be used to photochemically damage tumor cells via photothermal and photodynamic therapy [ 58 ]. A randomized phase II study of PEP02 MM , irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro—oesophageal junction adenocarcinoma. Hydrophobic and amphiphilic drug molecules can be kept inside of the liposomal nanoparticle via the creation of a polymeric encasement around the lipid bilayer. Depiction of the exchange of triethylamine for irinotecan, which forms a stable complex with sucrose octasulfate inside the liposome Reproduced with permission from [ 66 ]. Thermosensitive liposomes may allow the release of encapsulated drugs at specific temperatures [ 53 ].

J Natl Cancer Inst. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Co-loaded nanoparticles with bortezomib and doxorubicin were found to exhibit an antitumor synergistic effect on ovarian cancer [ 21 ]. Mechanism of polymeric nanoparticle-based drug transport across the blood—brain barrier BBB J Microencapsul. Tumor tissue is often characterized by leaky vasculature rich in fenestrations and poor in pericyte coverage. Ultrasound mediated delivery of drugs and genes to solid tumors. However, this effect may also pose a risk of nonspecific degradation, in which nanoparticles release drugs and other agents prior to arriving at target tumor tissue.

Patients in each arm were equally represented in terms of age, sex, country of origin, previous treatment, and primary tumor site gastric or GO junction. Cainelli F, Vallone A. Kaplan—Meier curves of overall and progression-free survival. These reactive oxygen species can induce damage to cellular materials and apoptosis occurs.

Cancer nanomedicine: a review of recent success in drug delivery

A wide variety of materials can be used to create nanoparticles for drug delivery. Nanocarriers may be modified to utilize passive and active targeting mechanisms to reach tumor tissue Fig.

A shows the adverse effects seen in Chang et al. A separate, multinational phase II study was conducted using liposomal irinotecan sucrosofate for patients with gemcitabine-refractory metastatic pancreatic cancer, the results of which led to a global phase III trial NAPOLI-1 [ 76 ].


The advent of nanomedicines represents significant advances in the field of drug delivery. The Kaplan—Meier estimates of overall and progression-free survival ab respectively in the intent-to-treat population for liposomal irinotecan PEP02irinotecan, and docetaxal Reproduced with permission from [ 69 ].

Many of these structures can be easily created and specifically designed, such as to include a wide range of optical properties.

Size, charge, and shape are all characteristics that affect the clearance of nanoparticles in kidneys.

f585 case study 2015

Diameter-selective Raman scattering from vibrational modes in carbon nanotubes. Once in the liposome, the irinotecan molecules form a stable complex with the SOS or Pn matrix, effectively allowing for an extremely high drug-to-lipid ratiomolecules per particle with a drug release half-life in the circulation of The use of stimuli-responsive systems may reduce non-specific exposure to chemotherapeutic drugs Fig.

Liposomal nanoparticles Liposome-based nanoparticles are spherical nanoparticles created via the use of lipid bilayers.

Reproducible, large-scale synthesis of nanomedicines is still a challenge for the distribution of a homogeneous batch of nanomedicines, especially when considering that these nano-platforms often require specific conditions for production via self-assembly. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. The nanomaterials available for cancer research can be modified in size, shape, and surface characteristics for customization to treat specific tumors.

Cancer nanomedicine: a review of recent success in drug delivery

This effect blocks DNA replication, inhibiting nucleic acid synthesis and inducing the DNA strands to break apart, ultimately causing cell death in proliferating cells [ 6263 ]. Differentiation between cancer cells within the same tumor can also occur.

f585 case study 2015

Cross collaborations between theoretical and experimental scientists across academia, with the pharmaceutical industry, medical doctors and the regulatory etudy will help translate more findings from the lab to the clinic and usher in the next era of clinical cancer nanomedicines. Please review our privacy policy.


F585 Case Study

Only one patient stuey seen to have a reaction after infusion. Targeting Nanocarriers may be modified to utilize passive and active targeting mechanisms to reach tumor tissue Fig. Positively charged nanoparticles were previously shown to most effectively target tumor vessels, but a switch to a neutral charge after extravasation allowed quicker diffusion of the nanoparticles to the tumor tissue [ 8 ].

The irinotecan molecules diffused into the liposomes readily; a triethylammonium TEA salt was used in a cation exchange mechanism to make up for the influx of drug molecules. National Center for Biotechnology InformationU.

f585 case study 2015

Study of nanoliposomal irinotecan Nal-IRI -containing regimens in patients with previously untreated, metastatic pancreatic adenocarcinoma; Sep 10 [about 6 screens]. Tumors typically have a hypoxic microenvironment with low oxygen and nutrient levels and thus high levels of reductive agents, such as glutathione [ 13 — 15 ]. A phase II study of weekly Genexol-PM in patients with hepatocelluar carcinoma after failure of sorafenib; Dec 29 [about 6 screens].

By itself, BPD is biocompatible. Ultrasound mediated delivery of drugs and genes to solid tumors. Storage of these nanomedicines under appropriate conditions is also critical since colloidal instability can dramatically alter their performance in vivo.

Useful Links – APT Initiatives

Changes in pH, redox, ionic strength, and stress in target tissues are examples of internal stimuli [ 3 ]. In a global randomized phase III trial Czsepatients with metastatic pancreatic ductal adenocarcinoma were randomly assigned one of two arms as a second-line treatment following the first-line gemcitabine-based treatment [ 7677 ]. In order to further discuss clinical cancer nanomedicine, the approval of MM, a liposomal nanomedicine created to treat metastatic pancreatic cancer, is discussed.